MaaT Pharma · EURONEXT:MAAT

MaaT Pharma — Investor Presentation (March 2024)

31 slides from MaaT Pharma's investor presentation, March 2024

  1. Slide 1: Enhancing Survival through Microbiome Innovation

    Ma fat ——J MaaT Pharma rd Enhancing Survival through Microbionte ry y * Innovation ° 2

  2. Slide 2: Disclaimer

    MaaT Pharma Disclaimer This document has been prepared by Maa Pharma (the “Company*) andis for informationandbackgroundpurposesonly. While the information contained herein has been preparedin good faith, neither the Company, nor its shareholders, directors, officers, agents, employees, or advisors g

  3. Slide 3: A late-stage clinical biotech leading the way in microbiome therapies in oncology

    MaaT Pharma March 24 03 . ss . . . . . _ MaaT Pharma: A late-stage clinical biotech, leading the way in Microbiome therapies in oncology la > A LEADER Listed on Euronext (MAAT.PA) global leader in the development of Microbiome Ecosystem Therapies \ in oncology to enhance patient survival ZG Founded

  4. Slide 4: Host-Microbiota Interactions are Critical for a Functional Immune System

    MaaT Pharma Host - Microbiota Interactions are Critical for a Functional Immune System A rich and diversified gut ecosystem actively modulates the immune system functionality A diversified microbiome contributes to the education and modulation of our immune system throughout life Bacterial richness

  5. Slide 5: Low High Intermediate

    1,00 0,75 0,50 * * 0,25 0,00 0 200 400 600 Low High Intermediate

  6. Slide 6: A Step-by-Step Increasing Value Creation Strategy

    MaaT Pharma, March 24 A Step-by-Step Increasing Value Creation Strategy Backed by Leading Capabilities in Microbiome Drug Candidate Production 4 Driving near-term value with the donor-derived MET-N platform POOLING microbiota ggat Progressing next-generation co-cultured scalable MET-C platform © Mae

  7. Slide 7: Rapid build up to target blockbuster markets

    4 > MaaT Pharma March 24 o7 Rapid build up to target blockbuster markets x & MaaT03X é : : MaaT034 Multiple Fields re) ~1 to 5b€! MaaT033 ~ 1 _ - MaaT013 2) 500m€ ~200mé€! Spe. Ecosystem For Improvement of sur Spe. Indication 'PYS EUS, US

  8. Slide 8: Cutting-edge Research Engine Powered by Metagenomics and Al-driven Candidate Selections

    MaaT Pharma March 24 Cutting-edge Research Engine Powered by Metagenomics and Al-driven Candidate Selections (vata ) / oes ‘ Healthy donors XR ) fC .») ¥ oes tC r Leading Platform AI ENGINE selitent Y{ pata} for Microbiome Z atients A MET-N/PoC Discovery g ce | A] XR ©) S Literature (Observational)

  9. Slide 9: A robust and balanced pipeline allowing for regular milestones

    MaaT Pharma, March 24 og . . . . _ Arobust and balanced pipeline allowing for regular milestones Platform Program Indication Preclinical Phase! Phase ll Phase lll Upcoming milestone aGvHD ©PD EMAyFDA ? GI-ORR mid Q4 24 Short Term Milestones M2aTOIS 1O PoC Melanoma > Results H2.24/ H1.25 MET-N <4 Maa

  10. Slide 10: Driving near-term value with the donor-derived MET-N platform

    Driving near-term value with the donor- derived MET-N platform

  11. Slide 11: Microbiome Restoration with MaaT013: A Maximum-Density Product

    MaaT Pharma, 1 Microbiome Restoration with MaaT0O13: A Maximum-Density Product * for Fast Engraftment in Acute Situations C > Characteristics GE Administration Available Clinical Data + Curative approach PP Efficacy evaluation in EAP + MaaT013 has received Orphan Drug Designation from FDA and EMA +

  12. Slide 12: Aims to Enhance Survival in Patients with Steroid & Ruxolitinib Resistant aGvHD

    MaaT013 Aims to Enhance Survival in Patients with Steroid & Ruxolitinib * Resistant aGVHD through Gut Microbiota Restoration Intestinal dysbiosis is associated with higher mortality in hemato-oncology ! Chemotherapy Antibiotics > Irradiation > Immunosuppressors 50% cee Allogenic Hematopoietic Stem C

  13. Slide 13: ARES, a pivotal Phase 3 trial to treat aGvHD in 3rd line

    MaaT Pharma ARES, a pivotal Phase 8 trial to treat AGVHD in 3" line showing ~ “high efficacy and low toxicity” as concluded by the DSMB ea Treatment Period D1, 5, 10 Patients > Screening ith SR-Gl-aGvHD i _ _ — w acy (D4 to D4) MaaT013 administration 4th dose if relapse after response Refractory or

  14. Slide 14: Early Access Program (EAP) confirms impact on survival

    Early Access Program (EAP) confirms impact on survival when primary endpoint is achieved March 24 Global EAP populations GLORR Patients (%) Overall Survival Rate Survival (%) 6mo 12mo 100: { “x, Responders 60 4 uy 74% 54% 75 \ mn aan 7M 56% , “0 504 sl 47% All patients ay 36% 24% 20 26 0 0+ Mcr Mvoc

  15. Slide 15: MaaT033 - The oral ecosystem microbiome capsule for adjunctive and maintenance therapy

    Ensuring Optimal Microbiota Function: MaaTO33 - The oral ecosystem microbiome capsule for adjunctive and maintenance therapy Pooled microbiota: high-richness, high-diversity, full ecosystem, Characteristics Microbiome Ecosystem Therapy containing Butycore® Administration Oral (a lyophilized capsule)

  16. Slide 16: MaaT033 to ensure optimal gut microbiota to improve survival in patients receiving allo-HSCT

    MaaTO33 to ensure optimal gut microbiota to improve survival in patients ‘ receiving allo-HSCT Intestinal dysbiosis is associated with higher mortality in hemato-oncology' = far] e Chemotherapy Antibiotics United States EU5 Japan — Allogenic Hematopoietic > Irradiation Stem Cell Transplantation > Im

  17. Slide 17: Phase 2b PHOEBUS designed to establish MaaT033 as an adjunctive treatment

    Phase 2b PHOEBUS designed to establish MaaTO33 as an adjunctive treatment for patients receiving allo-HSCT 387 patients ina study Atleast targeted globally patients dosed pre- Pre allo-HSCT and post- allo- treatment phase HSCT 15-2Idays Neutrophilrecovery Primary endpoint: Study started in of MaaT03

  18. Slide 18: MaaT033 to slow down Amyotrophic Lateral Sclerosis progression

    MaaT Pharma March 24 18 MaaT0O33 to slow down Amyotrophic Lateral Sclerosis progression ASO * Amyotrophic Lateral Sclerosis Rationale for Exploratory Utilization of MaaTO33 in ALS > Could affect up to 60,000 patients in US & EU by 20401 ~ Microbiota-Gut-Brain axis has the potential to become the new

  19. Slide 19: Progressing next-generation co-cultured donor independent scalable MET-C platform

    Progressing next- generation co-cultured donor independent scalable MET-C platform MET-C

  20. Slide 20: MET-C product generation is driven by predictive AI and in vitro and in vivo validation

    MaaT Pharma, March 24 20 MET-C product generation is driven by predictive Al and by state-of-the-art x proprietary in vitro and in vivo validation In silico Data Drug discovery Drug development Indication-specific Donor independent drug candidates Clinical & host ecosystem candidate parameters data

  21. Slide 21: Boosting Cancer Therapy: MaaT034 Donor-Independent Synthetic Microbiota

    March 24 ai Boosting Cancer Therapy: MaaT034 - Ground-breaking, Donor-Independent, Full ~* Ecosystem Synthetic Microbiota to Optimize Immune Checkpoint Inhibitor Treatment C > Characteristics (© 02 Administration Development Program First clinical batches manufactured expected in H2.2024 First in Hu

  22. Slide 22: A diverse gut microbiome increases survival in patients receiving Immune Checkpoint Inhibitors

    4a A diverse gut microbiome increases survival in patients receiving Immune Checkpoint Inhibitors (ICI) 22 Higher microbiome richness —> better response rate to ICI in patients with metastatic melanoma Proportion surviving Progression-free — High Intermediate 1.0 Low 0.5: if 0. to} 200 400 600 FMT f

  23. Slide 23: Proof of concept study with MaaT013 to improve ICI response

    March 24 23 MaaT Pharma . . _ Proof of concept study with MaaTO13 to improve ICI response c MaaTOo13 Bolative ( Ongoing Phase 2a PICASSO trial in collaboration with >) abundai Low Faecalibacteriu Bifidobacterium | @ ‘ich Assistance Publique - Hépitaux de Paris (sponsor) on ~ RCT [MaaT013 + ICI] vs.

  24. Slide 24: Envisioning the Future: MaaT03X Tailor-made Al-driven Synthetic Microbiota

    MaaT Pharma, March 24 24 Envisioning the Future: MaaTO3X —Tailor-made Al-driven Super-Competent x Synthetic Microbiota for specific indications ~\ Characteristics Administration Program Precision Medicine Current indication Development High richness, co-cultured, Super-competent full ecosystem micro

  25. Slide 25: End-to-End in-house cGMP manufacturing

    End-to-End in-house cGMP manufacturing All MET

  26. Slide 26: Building Europe's largest specialized cGMP manufacturing facility for Microbiome Ecosystem Therapies

    Building Europe’s . largest specialized Fully integrated Manufacturing and development cG M P man ufactu ri ng platform for a streamlined product development, facility for Microbiome See UDEMNE MP sieeSeSs Ecosystem Therapies Building a dedicated 1,600m2 site (expandable) to support demands until 20

  27. Slide 27: Key

    Key

  28. Slide 28: Meaningful milestones in both the near and long term

    MaaT Pharma, Meaningful milestones in both the near and long term 2024 28 MaaT013 (pooled enema) GvHD | EAP long term follow-up EBMT24 GvHD | ARES P3 G-LORR mid Q4 24 lO Mela. | PICASSO P2a Results H2.24/H1.25 C (os) MaaT013 (pooled enema) MaaT013 (pooled enema) GvHD | Final Results (OS) GvHD | Comm

  29. Slide 29: A Step-by-Step Increasing Value Creation Strategy

    MaaT Pharma, March 24 A Step-by-Step Increasing Value Creation Strategy Backed by Leading Capabilities in Microbiome Drug-Candidate Production MET-N MET-C MaaT03X MaaT034 oo MaaT033 CH MaaT013 & Ad bi P. tents ° © Co-cultured caps. Co-cultured capsule atients Pooled enema Pooled capsule Synthetic eu

  30. Slide 30: Corporate Social Responsibility

    MaaT Pharma, Corporate Social x Responsibility MaaT Pharma aims to become the source of Microbiome excellence providing patients with safe and innovative medicines. The Company develops products from sustainable biological matters, driving optimal impact of Microbiome. ‘coo 08S ND Inv ATONAXD resus

  31. Slide 31: Thank you

    Thank you invest@maat-pharma.com

MaaT Pharma — Investor Presentation (March 2024) on 6ix